Table 3.

Comparison of infants undergoing 3 different approaches before and after the onset of the COVID-19 pandemic in March 2020. Numbers are representing either average number of patients or percentage of patients (as indicated) as reported every other month.

Variable	Pre (N=117)	Post (N=226)	p-value*
Hearing Targeted: Number of patients with failed NBHS	34 (32.1)	36 (37.1)	0.63
Hearing Targeted: Number of patients tested	26.6 (28.5)	29.7 (34.3)	0.39
Hearing Targeted: Percent of failed NBHS who are tested	76.8% (22.5%)	76.3% (25.5%)	0.87
Hearing Targeted: Number of patients CMV Positive	0.4 (0.9)	0.4 (0.9)	0.98
Hearing Targeted: Percent of Tested Who Are Positive	3.9% (13.5%)	5.7% (19.7%)	0.35
Universal: Number Tested	762.3 (126.3)	387 (265.7)	0.005
Universal: CMV Positive	4.5 (1.8)	1 (0.9)	0.003
Universal: Percent of tested who are positive	0.6% (0.3%)	0.3% (0.3%)	0.072
Dry Blood Spot: Total number tested	8.7 (10.9)	7.6 (8.7)	0.70
Dry Blood Spot: Total number of CMV Positive	0.6 (1.2)	0.6 (1.1)	0.93
Dry Blood Spot: Percent of tested who are positive	8.7% (22.8%)	13.7% (31.7%)	0.47

^*All tests are t-test.

All summaries are mean (standard deviation).